First Trust Global Funds PLC has published its latest UK regulatory announcement, disclosing updated net asset values (NAVs) across its exchange‑traded funds. The report includes figures for the Bloomberg Nuclear Power UCITS ETF and the NYSE Arca Biotechnology UCITS ETF, reflecting performance as of late May.
The Bloomberg Nuclear Power UCITS ETF reported a NAV of $2,981,914.99 with a per‑share value of $19.879. Meanwhile, the NYSE Arca Biotechnology UCITS ETF recorded a NAV of $12,395,751.19, translating to $26.096 per share. Both funds are denominated in USD and continue to attract investor interest in specialized sectors.
These disclosures are part of routine UK regulatory requirements, ensuring transparency for investors. The figures highlight steady growth in nuclear power investments amid global clean energy initiatives, while biotechnology remains resilient thanks to ongoing innovation in healthcare and pharmaceuticals.
For investors, the NAV updates provide a snapshot of fund valuation and sector momentum, reinforcing First Trust’s commitment to transparency and compliance in the UCITS ETF market.
